Equity Long-Short

Mo Aziz

Capital markets veteran with 25 years across sell-side and buy-side research, investor relations, and fund management. Currently publish independent equity research (Mofferies Investment Research, via Smartkarma) spanning semiconductor memory (DRAM/NAND/HBM), foundry, semiconductor equipment and advanced packaging, gold and cross-asset strategy, financials forensics, and APAC IPOs — with a standing watchlist of 190+ companies across 41 countries. Background includes deep aviation-sector expertise (airlines, airports, OEMs, lessors, air cargo, travel/OTAs). Approach centers on identifying cyclical inflection points and mispriced risk across sectors, translated into explicit, actionable calls.

Equity Bottom-Up

<ul>
<li>Valuation detachment: Every conventional metric — P/E, EV/EBITDA, P/FCF — the current price cannot be grounded in earnings. The premium is a bet on revenues that do not yet exist</li>
<li>Analysts prices Tesla on two entirely different frameworks — one anchored to cash flows, one to a platform yet to be built. Thus far, the platform camp is up.</li>
<li>Tesla's 5-year beta is ~2.3x. In 2022 the stock fell 65% while the S&amp;P lost 19%. When risk appetite retreats, TSLA tends to lead the move lower.</li>
</ul>


Valuation detachment: Every conventional metric — P/E, EV/EBITDA, P/FCF — the current price cannot be grounded in earnings. The premium is a bet on revenues that do not yet exist
Analysts prices Tesla on two entirely different frameworks — one anchored to cash flows, one to a platform yet to be built. Thus far, the platform camp is up.
Tesla's 5-year beta is ~2.3x. In 2022 the stock fell 65% while the S&amp;P lost 19%. When risk appetite retreats, TSLA tends to lead the move lower.


TESLA (TSLA US): A Forensic Valuation of the World's Most Contested Stock